Daptomycin is named as an intervention in 2 current clinical trials in our Canada, Australia, Germany, France, Netherlands, Sweden, Japan, Singapore and Israel registers. 2 are recruiting patients now. All registered phases are Phase 4. The sponsor with the most trials is University of Melbourne (1). The most-studied condition is Staphylococcus Aureus Bacteremia. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Staphylococcus Aureus Network Adaptive Platform Trial
NCT05137119 · ClinicalTrials.gov ↗ · Staphylococcus Aureus Bacteremia
|
Phase 4 | Recruiting | University of Melbourne | Germany, France, Netherlands, Sweden, Canada, Japan, Singapore, Australia, Israel |
|
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
NCT06637332 · ClinicalTrials.gov ↗ · Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia
|
Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Daptomycin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
|
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
2025-520940-14-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 4 | Authorised | Assistance Publique Hopitaux De Paris | France |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
16 single-substance products containing Daptomycin on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| University of Melbourne | 1 |
| Todd C. Lee MD MPH FIDSA | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Canada, Australia, Germany, France, Netherlands, Sweden, Japan, Singapore and Israel registers name Daptomycin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in Canada, 2 with sites in Australia, 1 with sites in Germany, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Sweden, 1 with sites in Japan, 1 with sites in Singapore and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of Melbourne (1) and Todd C. Lee MD MPH FIDSA (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 16 single-substance products containing Daptomycin, for example Daptomycin 350 mg powder for solution for injection/infusion (Reddy Holding GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Daptomycin: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Daptomycin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Daptomycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Daptomycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.